The emerging fungal pathogen, Cryptococcus gattii, causes infections in both immunocompromised and immunocompetent individuals, often resulting in high mortality rates. While Cryptococcus neoformans is predominantly associated with cryptococcosis in immunocompromised patients, the significance of C. gattii infections has garnered attention due to its prevalence among seemingly healthy individuals. Notably, C. gattii exhibits distinct epidemiological patterns, geographic distribution, genotypes, and phenotypes compared to C. neoformans. However, the comprehension of C. gattii's virulence characteristics, regulatory mechanisms, and therapeutic avenues has lagged behind those of C. neoformans. The less robust clinical and epidemiological data, coupled with the limitations of effective treatment options, underscore the urgency in addressing C. gattii as a serious public health threat. In this review, I discuss the epidemiology, virulence factors, regulatory mechanisms, immunomodulatory attributes, and drug susceptibility of C. gattii. This comprehensive discussion aims to enhance our understanding of this emerging fungal pathogen and potentially contribute to the development of more effective prevention and management strategies.